Compare
ImmunityBio, Inc. vs Agenus Inc vs Autolus Therapeutics plc vs REGENXBIO Inc.
| Latest fiscal year | ImmunityBio, Inc. IBRX | Agenus Inc AGEN | Autolus Therapeutics plc AUTL | REGENXBIO Inc. RGNX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $113.29M | $114.20M | $75.39M | $170.44M |
| Revenue growth (YoY) | +668.3% | +10.4% | +644.9% | +104.5% |
| Gross margin | n/a | n/a | -27.8% (computed) | n/a |
| Operating margin | -226.0% | -17.7% | -358.9% | -94.6% |
| Net margin | -310.2% | -2.7% | -381.4% | -113.8% |
| Net income | -$351.40M | -$3.08M | -$287.53M | -$193.88M |
| EPS (Diluted) | -$0.38 | $0.00 | -$1.08 | -$3.76 |
| Operating cash flow | -$304.94M | -$77.19M | -$283.57M | -$123.96M |
| Free cash flow | -$308.78M | -$77.20M | -$302.61M | -$126.38M |
| Cash & equivalents | $88.33M | $3.00M | $104.13M | $34.47M |
| Total assets | $501.90M | $226.80M | $589.07M | $453.03M |
| Total liabilities | $1.00B | n/a | $410.94M | $350.30M |
| Shareholders' equity | -$500.47M | -$271.11M | $178.13M | $102.73M |
| Return on year-end equity | n/a | n/a | -161.4% | -188.7% |
| Shares outstanding | 1.01B | 35.32M | n/a | 50.89M |
Revenue, most recent five fiscal years
| Fiscal year | ImmunityBio, Inc. | Agenus Inc | Autolus Therapeutics plc | REGENXBIO Inc. |
|---|---|---|---|---|
| Latest | $113.29M Ended 2025-12-31 | $114.20M Ended 2025-12-31 | $75.39M Ended 2025-12-31 | $170.44M Ended 2025-12-31 |
| 1 year earlier | $14.74M Ended 2024-12-31 | $103.46M Ended 2024-12-31 | $10.12M Ended 2024-12-31 | $83.33M Ended 2024-12-31 |
| 2 years earlier | $622.0K Ended 2023-12-31 | $156.31M Ended 2023-12-31 | $1.70M Ended 2023-12-31 | $90.24M Ended 2023-12-31 |
| 3 years earlier | $240.0K Ended 2022-12-31 | $98.02M Ended 2022-12-31 | n/a | $112.72M Ended 2022-12-31 |
| 4 years earlier | $934.0K Ended 2021-12-31 | $295.67M Ended 2021-12-31 | n/a | $470.35M Ended 2021-12-31 |